JP6475624B2 - 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 - Google Patents

高血圧症及び高カリウム血症を治療するためのカリウム結合剤 Download PDF

Info

Publication number
JP6475624B2
JP6475624B2 JP2015535893A JP2015535893A JP6475624B2 JP 6475624 B2 JP6475624 B2 JP 6475624B2 JP 2015535893 A JP2015535893 A JP 2015535893A JP 2015535893 A JP2015535893 A JP 2015535893A JP 6475624 B2 JP6475624 B2 JP 6475624B2
Authority
JP
Japan
Prior art keywords
patient
composition
treatment
potassium
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015535893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500672A (ja
Inventor
ゲリット クラーナー，
ゲリット クラーナー，
ランス ベルマン，
ランス ベルマン，
Original Assignee
レリプサ， インコーポレイテッド
レリプサ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6475624(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by レリプサ， インコーポレイテッド, レリプサ， インコーポレイテッド filed Critical レリプサ， インコーポレイテッド
Publication of JP2016500672A publication Critical patent/JP2016500672A/ja
Application granted granted Critical
Publication of JP6475624B2 publication Critical patent/JP6475624B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2015535893A 2012-10-08 2013-10-08 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 Active JP6475624B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711184P 2012-10-08 2012-10-08
US61/711,184 2012-10-08
PCT/US2013/063921 WO2014058905A2 (en) 2012-10-08 2013-10-08 Potassium-binding agents for treating hypertension and hyperkalemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017255122A Division JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Publications (2)

Publication Number Publication Date
JP2016500672A JP2016500672A (ja) 2016-01-14
JP6475624B2 true JP6475624B2 (ja) 2019-02-27

Family

ID=49385427

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535893A Active JP6475624B2 (ja) 2012-10-08 2013-10-08 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2017255122A Active JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2020134733A Active JP7113871B2 (ja) 2012-10-08 2020-08-07 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2021053174A Withdrawn JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017255122A Active JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2020134733A Active JP7113871B2 (ja) 2012-10-08 2020-08-07 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2021053174A Withdrawn JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Country Status (10)

Country Link
US (6) US10813946B2 (enExample)
EP (1) EP2916851B1 (enExample)
JP (4) JP6475624B2 (enExample)
KR (2) KR20210005314A (enExample)
CN (2) CN104822383A (enExample)
AU (3) AU2013329451B2 (enExample)
BR (1) BR112015007749A2 (enExample)
CA (1) CA2886788C (enExample)
HK (1) HK1210705A1 (enExample)
WO (1) WO2014058905A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
AU2013329451B2 (en) 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
ITUB20159278A1 (it) * 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN115427383B (zh) * 2020-03-27 2025-08-26 维福(国际)有限公司 2-氟丙烯酸甲酯的合成
CN111978590B (zh) * 2020-09-04 2021-02-12 四川大学 一种沸石-肝素模拟聚合物共混微球、其制备方法及其应用
KR102647158B1 (ko) 2021-03-24 2024-03-15 강원대학교산학협력단 신규한 페디오코커스 악시딜락티시 균주 및 상기 균주를 이용하여 발효시킨 대두 발효물의 다양한 용도
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487958A (en) * 1892-12-13 Patrick mccann
US2340111A (en) 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (enExample) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4191812A (en) 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
ES2070307T3 (es) 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
HUT72658A (en) 1992-08-20 1996-05-28 Du Pont Crosslinked polymeric ammonium salts and pharmaceutical compositions containing them
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH09506342A (ja) 1993-11-25 1997-06-24 サルテルナテ・ベー・ブイ 一価カチオンに結合する粒子、並びにナトリウムおよび／またはカリウムイオンを捕捉して除去するための上記粒子の使用および方法
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
EP0910351A1 (en) 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
US6280717B1 (en) 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
EA003782B1 (ru) 1998-11-06 2003-08-28 Дж.Д.Сирл Энд Ко. Комбинированная терапия с применением ингибитора фермента конверсии ангиотензина и антагониста альдостерона для снижения заболеваемости и смертности при сердечно-сосудистых заболеваниях
WO2000040224A1 (en) 1999-01-07 2000-07-13 Elan Corporation, Plc Multiparticulate oral dosage forms
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US6569910B1 (en) 1999-10-27 2003-05-27 Basf Aktiengesellschaft Ion exchange resins and methods of making the same
AU780873B2 (en) 2000-01-14 2005-04-21 Otsuka Pharmaceutical Factory, Inc. Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
US6908609B2 (en) 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US7566799B2 (en) 2001-10-01 2009-07-28 Basf Aktiengesellschaft Process for the preparation of alkylaryl compounds and sulfonates thereof
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
CA2516457C (en) 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
JP2007517047A (ja) 2003-12-31 2007-06-28 ジェンザイム・コーポレーション 腸溶コーティングされた脂肪族アミンポリマーの胆汁酸捕捉因子
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
GB2430368B (en) 2004-03-30 2009-08-26 Ilypsa Inc Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
CN101316601A (zh) 2005-09-30 2008-12-03 伊立普萨公司 从哺乳动物的胃肠道选择性除去钾离子的方法和组合物
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN101321519A (zh) 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
EP2601981A1 (en) 2007-08-29 2013-06-12 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
CN103919792B (zh) 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20120107381A1 (en) 2009-05-13 2012-05-03 Relypsa, Inc. Powder formulations of potassium-binding active agents
TR201807469T4 (tr) 2010-03-20 2018-06-21 Relypsa Inc Polifloroakrilat partikülleri hazırlamaya yönelik kesintisiz işlem.
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8697132B2 (en) * 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CA2824391A1 (en) 2011-01-10 2012-07-19 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and a base, uses thereof
SMT201900037T1 (it) * 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
CN103717567A (zh) 2011-06-27 2014-04-09 瑞立普萨公司 丙烯酸酯及衍生物的氟化
RU2618220C2 (ru) 2011-06-27 2017-05-03 Релипса, Инк. Способ преобразования полимера сложного эфира в полимерную кислоту
US20150196585A1 (en) * 2012-07-19 2015-07-16 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
AU2013329451B2 (en) 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia

Also Published As

Publication number Publication date
CN104822383A (zh) 2015-08-05
JP2018048211A (ja) 2018-03-29
KR20150088243A (ko) 2015-07-31
HK1210705A1 (en) 2016-05-06
EP2916851B1 (en) 2025-12-17
JP2021095421A (ja) 2021-06-24
JP7113871B2 (ja) 2022-08-05
US20210038636A1 (en) 2021-02-11
AU2020294307A1 (en) 2021-02-18
WO2014058905A2 (en) 2014-04-17
US11123363B2 (en) 2021-09-21
US10813946B2 (en) 2020-10-27
AU2013329451A1 (en) 2015-04-23
US9492476B2 (en) 2016-11-15
EP2916851A2 (en) 2015-09-16
AU2013329451B2 (en) 2018-08-09
CA2886788C (en) 2022-04-19
AU2020294307B2 (en) 2022-06-02
US20140105848A1 (en) 2014-04-17
JP2016500672A (ja) 2016-01-14
CA2886788A1 (en) 2014-04-17
US20180193377A1 (en) 2018-07-12
KR20210005314A (ko) 2021-01-13
US20210046104A1 (en) 2021-02-18
US20170020916A1 (en) 2017-01-26
JP6817185B2 (ja) 2021-01-20
JP2020176155A (ja) 2020-10-29
AU2018260862A1 (en) 2018-12-06
WO2014058905A3 (en) 2014-10-30
BR112015007749A2 (pt) 2017-07-04
AU2018260862B2 (en) 2020-10-08
US9925212B2 (en) 2018-03-27
US20150110886A1 (en) 2015-04-23
CN119405686A (zh) 2025-02-11

Similar Documents

Publication Publication Date Title
JP6475624B2 (ja) 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP5883471B2 (ja) 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190201

R150 Certificate of patent or registration of utility model

Ref document number: 6475624

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250